(NASDAQ: MAZE) Maze Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Maze Therapeutics's earnings in 2026 is -$122,542,000.On average, 12 Wall Street analysts forecast MAZE's earnings for 2026 to be -$160,949,554, with the lowest MAZE earnings forecast at -$182,783,259, and the highest MAZE earnings forecast at -$138,307,807. On average, 12 Wall Street analysts forecast MAZE's earnings for 2027 to be -$190,188,455, with the lowest MAZE earnings forecast at -$244,072,601, and the highest MAZE earnings forecast at -$155,160,439.
In 2028, MAZE is forecast to generate -$216,355,694 in earnings, with the lowest earnings forecast at -$342,244,025 and the highest earnings forecast at -$154,579,314.